Suneel Gupta - May 31, 2023 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Chief Development Officer
Signature
/s/ Matthew Gosling, Attorney-in-Fact for Suneel Gupta
Stock symbol
PTGX
Transactions as of
May 31, 2023
Transactions value $
-$108,191
Form type
4
Date filed
6/2/2023, 07:51 PM
Previous filing
Jan 18, 2023
Next filing
Oct 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Award $0 +12K +8.56% $0.00 152K May 31, 2023 Direct F1, F2, F3
transaction PTGX Common Stock Tax liability -$108K -4.15K -2.73% $26.07 148K May 31, 2023 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents settlement by the Issuer of performance stock units ("PSUs") granted to the Reporting Person under the Company's 2016 Equity Incentive Plan on May 31, 2022, which vested based on the Issuer's achievement of corporate performance objectives.
F2 The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the "Lock-up Date") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date.
F3 Includes an aggregate of 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2023.
F4 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of PSUs.